PARP1 and cancer: Clinical trials expanded the use of PARP inhibitor monotherapy to cancers with defects other than BRCA mutation in the double-strand repair pathway and other forms of genomic instability, since these cancers seem to be more dependent on PARP1 to maintain genomic integrity [117].